Tags

Type your tag names separated by a space and hit enter

Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
J Clin Pharm Ther. 2005 Apr; 30(2):133-8.JC

Abstract

BACKGROUND

Depression is an international public health problem. The aim of this study was to compare the efficacy and tolerability of mirtazapine and fluoxetine treatment in a sample population consisting of Iranian patients suffering major depressive disorder.

METHODS

Thirty-six inpatients and outpatients with a diagnosis of major depressive disorder (Diagnostic and Statistical Manual of Mental Disorders-IV) and a score > or = 18 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17) were randomly assigned to 6 weeks of treatment with mirtazapine (30 mg/day) or fluoxetine (20 mg/day). Efficacy was assessed by HAM-D-17. Information about adverse events was obtained by questioning of participants and/or their examination. Assessments were performed at weeks 0, 1, 2, 3, 4 and 6.

RESULTS

Sixteen of mirtazapine-treated patients and fifteen of fluoxetine-treated patients completed the 6-week study period. Both treatment groups were well matched at baseline with respect to demographic and disease characteristics. Both drugs showed a significant improvement over the 6 weeks of treatment (P < 0.001). There was no statistically significant difference between the mean +/- SEM HAM-D scores of two groups at weeks 1, 2, 3, 4, and at the end point. There were no significant differences between two groups in terms of response to treatment (> or = 50% decrease from baseline in HAM-D-17 total score) and remission (HAM-D-17 score of < or = 7). None of the differences in reported adverse events was statistically significant.

CONCLUSION

In this study, mirtazapine and fluoxetine were equally effective and well tolerated after 6 weeks of treatment in patients with major depressive disorder.

Authors+Show Affiliations

Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran. amini-hom@sina.tums.ac.irNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15811165

Citation

Amini, H, et al. "Comparison of Mirtazapine and Fluoxetine in the Treatment of Major Depressive Disorder: a Double-blind, Randomized Trial." Journal of Clinical Pharmacy and Therapeutics, vol. 30, no. 2, 2005, pp. 133-8.
Amini H, Aghayan S, Jalili SA, et al. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. J Clin Pharm Ther. 2005;30(2):133-8.
Amini, H., Aghayan, S., Jalili, S. A., Akhondzadeh, S., Yahyazadeh, O., & Pakravan-Nejad, M. (2005). Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. Journal of Clinical Pharmacy and Therapeutics, 30(2), 133-8.
Amini H, et al. Comparison of Mirtazapine and Fluoxetine in the Treatment of Major Depressive Disorder: a Double-blind, Randomized Trial. J Clin Pharm Ther. 2005;30(2):133-8. PubMed PMID: 15811165.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. AU - Amini,H, AU - Aghayan,S, AU - Jalili,S A, AU - Akhondzadeh,S, AU - Yahyazadeh,O, AU - Pakravan-Nejad,M, PY - 2005/4/7/pubmed PY - 2005/11/4/medline PY - 2005/4/7/entrez SP - 133 EP - 8 JF - Journal of clinical pharmacy and therapeutics JO - J Clin Pharm Ther VL - 30 IS - 2 N2 - BACKGROUND: Depression is an international public health problem. The aim of this study was to compare the efficacy and tolerability of mirtazapine and fluoxetine treatment in a sample population consisting of Iranian patients suffering major depressive disorder. METHODS: Thirty-six inpatients and outpatients with a diagnosis of major depressive disorder (Diagnostic and Statistical Manual of Mental Disorders-IV) and a score > or = 18 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17) were randomly assigned to 6 weeks of treatment with mirtazapine (30 mg/day) or fluoxetine (20 mg/day). Efficacy was assessed by HAM-D-17. Information about adverse events was obtained by questioning of participants and/or their examination. Assessments were performed at weeks 0, 1, 2, 3, 4 and 6. RESULTS: Sixteen of mirtazapine-treated patients and fifteen of fluoxetine-treated patients completed the 6-week study period. Both treatment groups were well matched at baseline with respect to demographic and disease characteristics. Both drugs showed a significant improvement over the 6 weeks of treatment (P < 0.001). There was no statistically significant difference between the mean +/- SEM HAM-D scores of two groups at weeks 1, 2, 3, 4, and at the end point. There were no significant differences between two groups in terms of response to treatment (> or = 50% decrease from baseline in HAM-D-17 total score) and remission (HAM-D-17 score of < or = 7). None of the differences in reported adverse events was statistically significant. CONCLUSION: In this study, mirtazapine and fluoxetine were equally effective and well tolerated after 6 weeks of treatment in patients with major depressive disorder. SN - 0269-4727 UR - https://www.unboundmedicine.com/medline/citation/15811165/Comparison_of_mirtazapine_and_fluoxetine_in_the_treatment_of_major_depressive_disorder:_a_double_blind_randomized_trial_ L2 - https://doi.org/10.1111/j.1365-2710.2004.00585.x DB - PRIME DP - Unbound Medicine ER -